China's medical products administrator granted Hutchmed (HKG:0013) breakthrough therapy designation for its combination of savolitinib and osimertinib for a mutation of non-small cell lung cancer, according to a Thursday filing with the Hong Kong Exchange.

The drug combination is undergoing phase 3 trials in China, the filing said.

The breakthrough designation is given to drugs that treat life-threatening illnesses with no known treatment options and with clinical evidence showing advantages over other existing therapies, the filing said.